TABLE 2.

Age and baseline assessment of agitation and pain in the patients enrolled in the trial and subsequently allocated to the NanoBEO and placebo groups.

Baseline characteristics	NanoBEO group (n = 14)	Placebo group (n = 16)	Statistical analysis: p-Value and 95% CI
Age (mean ± SD)	86.07 ± 7.26	87.50 ± 6.68	0.58 t-test
CMAI-frequency (F; median)	50.50	50.50	0.64 (−21.00; −11.00) MWU test
CMAI-disruptiveness (D; median)	43.00	43.00	0.43 (−14.00; −6.00) MWU test
I-MOBID2 (median)	5.5	3.00	0.17 (−3.00; 1.00) MWU test

SD, standard deviation; CI, confidence intervals; I-MOBID2, Italian Mobilization–Observation–Behavior–Intensity–Dementia; MWU, Mann–Whitney U test.